Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camilla Qvortrup

Showing results (31-40 of 64) with videos related to

Pageof 7
Sort By:
Eclinicalmedicine|March 18, 2024
TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without bevacizumab in previously treated patients with esophago-gastric adenocarcinoma, a randomised phase III trialLene Baeksgaard Jensen, Mette Yilmaz, Marianne Nordsmark, et al.
Clinical Colorectal Cancer|May 10, 2015
Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation GroupPer Pfeiffer, Hafdan Sorbye, Camilla Qvortrup, et al.
Acta Oncologica (Stockholm, Sweden)|May 17, 2016
Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart reviewStine Braendegaard Winther, Kanita Zubcevic, Camilla Qvortrup, et al.
Journal of Neuromuscular Diseases|April 5, 2021
Oxaliplatin Neuropathy: Predictive Values of Skin Biopsy, QST and Nerve ConductionThomas Krøigård, Toke K Svendsen, Martin Wirenfeldt, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|December 3, 2025
The prognostic impact of lymph node yield in deficient and proficient mismatch repair colon cancers: A retrospective national cohort studyFrederik W Bækgaard, Anisoara Iordache, Andreas Hurup Nordholm, et al.
BJS Open|May 15, 2024
Neoadjuvant treatment of colorectal cancer: comprehensive reviewHenry G Smith, Per J Nilsson, Benjamin D Shogan, et al.
Acta Oncologica (Stockholm, Sweden)|November 27, 2019
Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian studyArtur Mezheyeuski, Fredrik Ponten, Per-Henrik Edqvist, et al.
Genes, Chromosomes & Cancer|April 24, 2024
Temporal trends and regional variability in BRAF and KRAS genetic testing in Denmark (2010-2022): Implications for precision medicineMatilde Grupe Frost, Kristoffer Jarlov Jensen, Espen Jimenez-Solem, et al.
Plos One|June 30, 2015
High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer CohortHalfdan Sorbye, Anca Dragomir, Magnus Sundström, et al.
The Lancet. Oncology|January 31, 2020
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trialPer Pfeiffer, Mette Yilmaz, Sören Möller, et al.
Pageof 7

Showing results (31-40 of 64) with videos related to

Sort By:
Pageof 7
Eclinicalmedicine|March 18, 2024
TRIFLURIDINE/TIPIRACIL (FTD/TPI) with or without bevacizumab in previously treated patients with esophago-gastric adenocarcinoma, a randomised phase III trialLene Baeksgaard Jensen, Mette Yilmaz, Marianne Nordsmark, et al.
Clinical Colorectal Cancer|May 10, 2015
Maintenance Therapy With Cetuximab Every Second Week in the First-Line Treatment of Metastatic Colorectal Cancer: The NORDIC-7.5 Study by the Nordic Colorectal Cancer Biomodulation GroupPer Pfeiffer, Hafdan Sorbye, Camilla Qvortrup, et al.
Acta Oncologica (Stockholm, Sweden)|May 17, 2016
Experience with S-1 in older Caucasian patients with metastatic colorectal cancer (mCRC): Findings from an observational chart reviewStine Braendegaard Winther, Kanita Zubcevic, Camilla Qvortrup, et al.
Journal of Neuromuscular Diseases|April 5, 2021
Oxaliplatin Neuropathy: Predictive Values of Skin Biopsy, QST and Nerve ConductionThomas Krøigård, Toke K Svendsen, Martin Wirenfeldt, et al.
Colorectal Disease : the Official Journal of the Association of Coloproctology of Great Britain and Ireland|December 3, 2025
The prognostic impact of lymph node yield in deficient and proficient mismatch repair colon cancers: A retrospective national cohort studyFrederik W Bækgaard, Anisoara Iordache, Andreas Hurup Nordholm, et al.
BJS Open|May 15, 2024
Neoadjuvant treatment of colorectal cancer: comprehensive reviewHenry G Smith, Per J Nilsson, Benjamin D Shogan, et al.
Acta Oncologica (Stockholm, Sweden)|November 27, 2019
Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: a population-based Scandinavian studyArtur Mezheyeuski, Fredrik Ponten, Per-Henrik Edqvist, et al.
Genes, Chromosomes & Cancer|April 24, 2024
Temporal trends and regional variability in BRAF and KRAS genetic testing in Denmark (2010-2022): Implications for precision medicineMatilde Grupe Frost, Kristoffer Jarlov Jensen, Espen Jimenez-Solem, et al.
Plos One|June 30, 2015
High BRAF Mutation Frequency and Marked Survival Differences in Subgroups According to KRAS/BRAF Mutation Status and Tumor Tissue Availability in a Prospective Population-Based Metastatic Colorectal Cancer CohortHalfdan Sorbye, Anca Dragomir, Magnus Sundström, et al.
The Lancet. Oncology|January 31, 2020
TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trialPer Pfeiffer, Mette Yilmaz, Sören Möller, et al.
Pageof 7